Tuberculosis and Respiratory Diseases

  • 제81권3호
  • /
  • Pages.198-215
  • /
  • 2018
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?

  • 투고 : 2018.04.22
  • 심사 : 2018.04.29
  • 발행 : 2018.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bronchodilators provide improvements in lung function and reductions in symptoms and exacerbations, and are the mainstay of pharmacological management of chronic obstructive pulmonary disease (COPD). The Global Initiative for Chronic Obstructive Lung Disease strategy recommends the use of a combination of long-acting ${\beta}_2-agonist$/long-acting muscarinic antagonists (LABA/LAMA) as the first-line treatment option in the majority of symptomatic patients with COPD. This review provides an indirect comparison of available LABA/LAMA fixed-dose combinations (FDCs) through discussion of important efficacy and safety data from the key literature, with the objective of providing physicians with a framework for informed decision-making. LABA/LAMA FDCs provided greater benefits compared with placebo and similar or greater benefits compared with tiotropium and salmeterol/fluticasone in improving lung function, dyspnea, health-related quality of life, reducing rescue medication use and preventing exacerbations, although with some variability in efficacy between individual FDCs; further, tolerability profiles were comparable among LABA/LAMA FDCs. However, there is a disparity in the amount of evidence generated for different LABA/LAMA FDCs. Thus, this review shows that all LABA/LAMA FDCs may not be the same and that care should be taken when extrapolating individual treatment outcomes to the entire drug class. It is important that physicians consider the efficacy gradient that exists among LABA/LAMA FDCs, and factors such as inhaler devices and potential biomarkers, when choosing the optimal bronchodilator treatment for long-term management of patients with COPD.

키워드

참고문헌

  1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol 2017;53:128-49.
  2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2018.
  3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboy- ans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128. https://doi.org/10.1016/S0140-6736(12)61728-0
  4. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96. https://doi.org/10.1016/S0140-6736(12)61729-2
  5. Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One 2016;11:e0152618. https://doi.org/10.1371/journal.pone.0152618
  6. Soriano JB, Lamprecht B, Ramirez AS, Martinez-Camblor P, Kaiser B, Alfageme I, et al. Mortality prediction in chronic ob- structive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med 2015;3:443-50. https://doi.org/10.1016/S2213-2600(15)00157-5
  7. World Health Organization. Projections of mortality and causes of death, 2015 and 2030. Geneva: World Health Organization; 2014.
  8. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57. https://doi.org/10.1016/S0140-6736(06)68770-9
  9. Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Lan LT, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med 2015;14:4. https://doi.org/10.1186/s12930-015-0020-9
  10. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest 2010;138: 20-31. https://doi.org/10.1378/chest.08-2114
  11. KalagoudaMahishale V, Angadi N, Metgudmath V, Lolly M, Eti A, Khan S. The prevalence of chronic obstructive pulmonary disease and the determinants of underdiagnosis in women exposed to biomass fuel in India: a cross section study. Chon- nam Med J 2016;52:117-22. https://doi.org/10.4068/cmj.2016.52.2.117
  12. Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, et al. Indacaterol/glycopyrronium versus salme- terol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis 2017;12:339-49. https://doi.org/10.2147/COPD.S125058
  13. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96. https://doi.org/10.1016/S0140-6736(07)61382-8
  14. Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005;23:345-63. https://doi.org/10.2165/00019053-200523040-00005
  15. Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis 2017;12:2291-305. https://doi.org/10.2147/COPD.S138554
  16. Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J 2016;47:625-37. https://doi.org/10.1183/13993003.01170-2015
  17. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125:249- 59. https://doi.org/10.1378/chest.125.1.249
  18. Miravitlles M, Anzueto A, Jardim JR. Optimizing bronchodilation in the prevention of COPD exacerbations. Respir Res 2017;18:125. https://doi.org/10.1186/s12931-017-0601-2
  19. Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, et al. Comparative efficacy of once-daily umeclidinium/ vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther 2017;34:2518-33. https://doi.org/10.1007/s12325-017-0626-4
  20. Sion KY, Huisman EL, Punekar YS, Naya I, Ismaila AS. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting ${\beta}2$-agonist (LABA) combinations in COPD. Pulm Ther 2017;3:297-316. https://doi.org/10.1007/s41030-017-0048-0
  21. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016;149:1181-96. https://doi.org/10.1016/j.chest.2016.02.646
  22. Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, et al. Dual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung 2017;195:739-47. https://doi.org/10.1007/s00408-017-0055-9
  23. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol 2017;53:324-35.
  24. Miravitlles M, Anzueto A. A new two-step algorithm for the treatment of COPD. Eur Respir J 2017;49:1602200. https://doi.org/10.1183/13993003.02200-2016
  25. Yoon HK, Park YB, Rhee CK, Lee JH, Oh YM; Committee of the Korean COPD Guideline 2014. Summary of the chronic obstructive pulmonary disease clinical practice guideline revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease. Tuberc Respir Dis 2017;80:230-40. https://doi.org/10.4046/trd.2017.80.3.230
  26. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodila- tor QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209. https://doi.org/10.1016/S2213-2600(13)70052-3
  27. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus sal- meterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015;10:1015-26.
  28. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34. https://doi.org/10.1056/NEJMoa1516385
  29. Calverley PM, Anzueto AR, Carter K, Gronke L, Hallmann C, Jenkins C, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DY- NAGITO): a double-blind, randomized, parallel-group, activecontrolled trial. Lancet Respir Med 2018;6:337-44. https://doi.org/10.1016/S2213-2600(18)30102-4
  30. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78.
  31. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45:969-79. https://doi.org/10.1183/09031936.00136014
  32. Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denen- berg M, O’Donnell DE, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med 2017;126:105-15. https://doi.org/10.1016/j.rmed.2017.03.015
  33. Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67. https://doi.org/10.1016/j.rmed.2013.05.016
  34. Asai K, Minakata Y, Hirata K, Fukuchi Y, Kitawaki T, Ikeda K, et al. QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study. Eur Respir J 2013;42:P3392.
  35. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94. https://doi.org/10.1183/09031936.00200212
  36. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLU- MINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60. https://doi.org/10.1016/S2213-2600(12)70052-8
  37. Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8.
  38. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/ vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538- 46. https://doi.org/10.1016/j.rmed.2013.06.001
  39. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145:981- 91. https://doi.org/10.1378/chest.13-1579
  40. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472- 86. https://doi.org/10.1016/S2213-2600(14)70065-7
  41. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752-60. https://doi.org/10.1016/j.rmed.2014.10.002
  42. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med 2015;15:91. https://doi.org/10.1186/s12890-015-0092-1
  43. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015;109:870-81. https://doi.org/10.1016/j.rmed.2015.04.018
  44. Beeh KM, Westerman J, Kirsten AM, Hebert J, Gronke L, Hamilton A, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015;32:53-9. https://doi.org/10.1016/j.pupt.2015.04.002
  45. Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015;109:1312-9. https://doi.org/10.1016/j.rmed.2015.08.002
  46. Beeh KM, Derom E, Echave-Sustaeta J, Gronke L, Hamil- ton A, Zhai D, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat((R)) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler((R)) (ENERGITO((R)) study). Int J Chron Obstruct Pulmon Dis 2016;11:193-205.
  47. Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLI- FORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014;14:178. https://doi.org/10.1186/1471-2466-14-178
  48. D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24- week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15:123. https://doi.org/10.1186/s12931-014-0123-0
  49. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J 2016;48:1030-9. https://doi.org/10.1183/13993003.00216-2016
  50. Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, et al. Efficacy and safety of glycopyrrolate/ formoterol metered dose inhaler formulated using cosuspension delivery technology in patients with COPD. Chest 2017;151:340-57. https://doi.org/10.1016/j.chest.2016.11.028
  51. Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Al- agappan VK, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43:1599-609. https://doi.org/10.1183/09031936.00124013
  52. Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015;70:311-9. https://doi.org/10.1136/thoraxjnl-2014-206345
  53. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;108:584-92. https://doi.org/10.1016/j.rmed.2014.01.006
  54. Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tet- zlaff K, et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax 2014;69(Suppl 2):A186-7.
  55. O’Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J 2017;49:1601348. https://doi.org/10.1183/13993003.01348-2016
  56. Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebocontrolled study design. BMJ Open 2016;6:e010106. https://doi.org/10.1136/bmjopen-2015-010106
  57. Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, et al. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial. Trials 2017;18:80. https://doi.org/10.1186/s13063-017-1800-3
  58. Zheng J, Zhong N, Newlands A, Church A, Goh AH. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis 2015;10:1753-67.
  59. Ichinose M, Taniguchi H, Takizawa A, Gronke L, Loaiza L, Voss F, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat((R)) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado((R)) studies. Int J Chron Obstruct Pulmon Dis 2016;11:2017-27. https://doi.org/10.2147/COPD.S110389
  60. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. Efficacy and safety of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone in Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the Chinese cohort from the LANTERN study. COPD 2016;13:686-92. https://doi.org/10.1080/15412555.2016.1182970
  61. Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig 2016;54:428-35. https://doi.org/10.1016/j.resinv.2016.06.006
  62. Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:1068- 79. https://doi.org/10.1164/rccm.201505-1048OC
  63. Ferguson GT, Taylor AF, Thach C, Wang Q, Schubert-Tennig- keit AA, Patalano F, et al. Long-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study. Chronic Obstr Pulm Dis 2016;3:716-28.
  64. Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res 2017;18:140. https://doi.org/10.1186/s12931-017-0622-x
  65. Frith P, Ashmawi S, Krishnamurthy S, Diaz D, Gurgun A, Hours-Zesiger P, et al. Assessing direct switch to indacaterol/ glycopyrronium from salmeterol/fluticasone in moderate to severe symptomatic COPD patients: the FLASH study. Respi- rology 2017;22(S3):70.
  66. Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498-507. https://doi.org/10.1016/j.rmed.2014.07.011
  67. Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs 2015;75:61-74. https://doi.org/10.1007/s40265-014-0326-1
  68. Naccarelli G, Finkle J, Chopra B, Brooks J, Harris S, Church A. Cardiovascular safety of umeclidinium/vilanterol in COPD: results from eight randomized clinical trials. Am J Respir Crit Care Med 2014;189:A3766.
  69. Buhl R, Tetzlaff K, Korducki L, Vogelmeier C, McGarvey L. Pooled safety analysis of adjudicated serious adverse events with the fixed-dose combination of tiotropium+olodaterol. Am J Respir Crit Care Med 2015;191:A5756.
  70. Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res 2017;18:196. https://doi.org/10.1186/s12931-017-0683-x
  71. Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Prim Care Respir J 2013;22:385-6. https://doi.org/10.4104/pcrj.2013.00097
  72. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010;5:401-6.
  73. Miravitlles M, Soler-Cataluna JJ, Alcazar B, Viejo JL, Garcia- Rio F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulm Pharmacol Ther 2018;48:97-103. https://doi.org/10.1016/j.pupt.2017.10.006
  74. Molimard M, Colthorpe P. Inhaler devices for chronic ob- structive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv 2015;28:219-28. https://doi.org/10.1089/jamp.2014.1142
  75. Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008;21:321-8. https://doi.org/10.1089/jamp.2007.0634
  76. Garcia-Rio F, Soler-Cataluna JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler de- vices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD 2017;14:573-80. https://doi.org/10.1080/15412555.2017.1365120
  77. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8. https://doi.org/10.1016/j.rmed.2011.01.005
  78. Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest 2016;150: 394-406. https://doi.org/10.1016/j.chest.2016.03.041
  79. Molimard M, Rherison C, Lamarque S, Lignot-Maleyran S, Balestra A, Chartier A, et al. Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients. Eur Respir J 2016;48:PA4078.
  80. Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled cor- ticosteroids in COPD and the risk reduction of pneumonia. Chest 2015;148:1177-83. https://doi.org/10.1378/chest.15-0627
  81. D’Urzo A, Donohue JF, Kardos P, Miravitlles M, Price D. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2015;16:1845-60. https://doi.org/10.1517/14656566.2015.1067682
  82. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42. https://doi.org/10.1016/S2213-2600(15)00106-X
  83. Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open 2016;6:e010099. https://doi.org/10.1136/bmjopen-2015-010099
  84. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523- 5. https://doi.org/10.1164/rccm.201502-0235LE
  85. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 2016;71:118-25. https://doi.org/10.1136/thoraxjnl-2015-207021
  86. Roche N, Chapman KR, Vogelmeier CF, Herth FJ, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial. Am J Respir Crit Care Med 2017;195:1189- 97. https://doi.org/10.1164/rccm.201701-0193OC
  87. Miravitlles M, Cosio BG, Arnedillo A, Calle M, Alcazar-Navarrete B, Gonzalez C, et al. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res 2017;18:198. https://doi.org/10.1186/s12931-017-0682-y

피인용 문헌

  1. Pharmacotherapy for chronic obstructive pulmonary disease vol.61, pp.9, 2018, https://doi.org/10.5124/jkma.2018.61.9.545
  2. The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy vol.92, pp.1, 2018, https://doi.org/10.26442/00403660.2020.01.000489
  3. Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study vol.16, pp.None, 2021, https://doi.org/10.2147/copd.s285385
  4. Comparative studies of dual bronchodilation in COPD vol.91, pp.1, 2018, https://doi.org/10.4081/monaldi.2021.1625
  5. Updated view on the treatment of chronic obstructive pulmonary disease in Korea vol.64, pp.3, 2018, https://doi.org/10.5124/jkma.2021.64.3.225
  6. Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment vol.10, pp.12, 2018, https://doi.org/10.3390/jcm10122649